CSRP2 and glioblastoma: Moreover, we found that GBM and/or LGG patients with high CSRP2 expression had a worse prognosis than those with low CSRP2 expression using Gravendeel (Fig. 1E), GEPIA (Fig. 1F), and CGGA datasets (Supplementary Fig. S2D), though there was no significant correlation between CSRP2 expression and GBM prognosis in TCGA and Rembrandt datasets (Supplementary Fig. S2E, F).